Analysis of serum microRNAs and rs2910164 GC single-nucleotide polymorphism of miRNA-146a in COVID-19 patients

ABSTRACT Alteration of micro-RNAs (miRNAs) expression, including miRNA-122a, −146a and −205 family members, can have profound effects on inflammatory and IFN pathways (miRNA-146a), known as hallmarks of COVID-19. SARS-CoV-2-infected patients were recruited at Policlinico Umberto I Hospital of Sapienza University of Rome (Italy). MiRNA‐122a, ‐146a, ‐205 and IFI27 (Interferon Alpha Inducible Protein 27) levels were screened in SARS-CoV-2 patients (n = 14) and healthy controls (n = 10) by real‐time RT‐PCR assays. Then, miRNA-146a rs2910164 GC single-nucleotide polymorphism (SNP) was genotyped in a larger group of COVID-19 patients (n = 129), and its relationship with severe disease [Intensive Care Unit (ICU) support or survival/death] was assessed. SARS-CoV-2-positive patients had increased PCR, D-Dimer and Fibrinogen levels compared to healthy controls (p < .05 for all measurements). MiRNA-122a and -146a serum levels were upregulated in COVID-19 patients (miRNA-122a: p = .002; miRNA-146a: p < .001). Decreased IFI27 levels were observed in COVID-19 patients with higher miRNA-146a levels (p = .047). Moreover, miRNA-146a rs2910164 C/G genotypes distributions were similar in COVID-19 patients and in validated European healthy subjects (n = 37,214). MiRNA-146a SNP was not associated with severe COVID-19 outcome (ICU or death). MiRNA-122a and -146a levels were elevated in SARS-CoV-2 infected patients, with miRNA-146a upregulation possibly contributing to IFN pathways dysregulation (e.g., reduced IFI27 levels) observed in severe COVID-19, although there is no evidence for the involvement of rs2910164 SNP.

[1]  W. Lukiw.  microRNA Heterogeneity, Innate-Immune Defense and the Efficacy of SARS-CoV-2 Infection—A Commentary , 2021, Non-coding RNA.

[2]  Joaquin Lopez-Orozco,et al.  SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors , 2021, Journal of virology.

[3]  Wei Zhao,et al.  Virus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19 , 2021, Frontiers in Immunology.

[4]  S. Johnston,et al.  miR-122 promotes virus-induced lung disease by targeting SOCS1 , 2021, JCI insight.

[5]  H. B. Baghi,et al.  Acute and post-acute phase of COVID-19: Analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC , 2021, International Immunopharmacology.

[6]  I. Fricke-Galindo,et al.  Genetics Insight for COVID-19 Susceptibility and Severity: A Review , 2021, Frontiers in Immunology.

[7]  M. Abbasifard,et al.  The relationship between serum levels of interleukin-2 and IL-8 with circulating microRNA-10b in patients with COVID-19. , 2021, Iranian journal of immunology : IJI.

[8]  G. Gao,et al.  Downregulated miR-451a as a feature of the plasma cfRNA landscape reveals regulatory networks of IL-6/IL-6R-associated cytokine storms in COVID-19 patients , 2021, Cellular & Molecular Immunology.

[9]  J. Schultze,et al.  COVID-19 and the human innate immune system , 2021, Cell.

[10]  C. Scagnolari,et al.  ACE2 expression is related to the interferon response in airway epithelial cells but is that functional for SARS-CoV-2 entry? , 2021, Cytokine.

[11]  C. Scagnolari,et al.  Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19) , 2021, Virus Research.

[12]  Yingfeng Zheng,et al.  The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID‐19 , 2020, Clinical and translational medicine.

[13]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[14]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[15]  Zhe Luo,et al.  D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study , 2020, Journal of Intensive Care.

[16]  Adam C. Labonte,et al.  Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway , 2020, Scientific Reports.

[17]  D. Acharya,et al.  Dysregulation of type I interferon responses in COVID-19 , 2020, Nature Reviews Immunology.

[18]  C. Scagnolari,et al.  Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients , 2020, Journal of Clinical Virology.

[19]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[20]  S. Mihm.  COVID-19: Possible Impact of the Genetic Background in IFNL Genes on Disease Outcomes , 2020, Journal of Innate Immunity.

[21]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[22]  Qiurong Ruan,et al.  Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[23]  A. Soleimani,et al.  Polymorphisms of Pre-miR-499 rs3746444 T/C and Pre-miR-146a rs2910164 C/G in the Autoimmune Diseases of Rheumatoid Arthritis and Systemic Lupus Erythematosus in the West of Iran , 2020, Iranian journal of public health.

[24]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[25]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[26]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[27]  Jing Liu,et al.  Asymptomatic cases in a family cluster with SARS-CoV-2 infection , 2020, The Lancet Infectious Diseases.

[28]  Tiantian Han,et al.  Coronavirus infections and immune responses , 2020, Journal of medical virology.

[29]  R. Liu,et al.  Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors , 2020, Emerging microbes & infections.

[30]  F. Jalil,et al.  Association of MIR146A rs2910164 variation with a predisposition to sporadic breast cancer in a Pakistani cohort , 2019, Annals of human genetics.

[31]  C. Scagnolari,et al.  Increased expression of IL-32 correlates with IFN-γ, Th1 and Tc1 in virologically suppressed HIV-1-infected patients. , 2019, Cytokine.

[32]  Junsong Zhang,et al.  Identification of potential diagnostic biomarkers for pneumonia caused by adenovirus infection in children by screening serum exosomal microRNAs , 2019, Molecular medicine reports.

[33]  Xiaofang Sun,et al.  Downregulation of miR-146a inhibits influenza A virus replication by enhancing the type I interferon response in vitro and in vivo. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[34]  Zhiwei Wu,et al.  Exosome-mediated miR-146a transfer suppresses type I interferon response and facilitates EV71 infection , 2017, PLoS pathogens.

[35]  C. Scagnolari,et al.  A pilot study on the effects of probiotic supplementation on neuropsychological performance and microRNA‐29a‐c levels in antiretroviral‐treated HIV‐1‐infected patients , 2017, Brain and behavior.

[36]  Zengfang Wang,et al.  Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer , 2017, Oncotarget.

[37]  Jianguo Li,et al.  MicroRNA-205‑5b inhibits HMGB1 expression in LPS-induced sepsis. , 2016, International journal of molecular medicine.

[38]  J. Ji,et al.  Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A meta-analysis , 2016, Autoimmunity.

[39]  Dongqing Xu,et al.  miR-146a negatively regulates NK cell functions via STAT1 signaling , 2016, Cellular &Molecular Immunology.

[40]  S. Kong,et al.  Identification of microRNAs in Throat Swab as the Biomarkers for Diagnosis of Influenza , 2016, International journal of medical sciences.

[41]  S. Booth,et al.  MicroRNA-146a: A Dominant, Negative Regulator of the Innate Immune Response , 2014, Front. Immunol..

[42]  G. Cheng,et al.  MicroRNAs: New Regulators of Toll-Like Receptor Signalling Pathways , 2014, BioMed research international.

[43]  You Li,et al.  The Functional Polymorphisms of miR-146a Are Associated with Susceptibility to Severe Sepsis in the Chinese Population , 2014, Mediators of inflammation.

[44]  J. Karrich,et al.  MicroRNA-146a regulates survival and maturation of human plasmacytoid dendritic cells. , 2013, Blood.

[45]  M. Cybulsky,et al.  MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways , 2013, EMBO molecular medicine.

[46]  G. Jicha,et al.  Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease , 2012, Experimental Neurology.

[47]  B. Ying,et al.  Genetic study of two single nucleotide polymorphisms within corresponding microRNAs and susceptibility to tuberculosis in a Chinese Tibetan and Han population. , 2011, Human immunology.

[48]  Eckart Meese,et al.  Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis , 2011, RNA biology.

[49]  Takahiro Tanaka,et al.  Biomarkers for Colorectal Cancer , 2010, International journal of molecular sciences.

[50]  A. Pivarcsi,et al.  microRNAs in Inflammation , 2009, International reviews of immunology.

[51]  Catalin Vasilescu,et al.  MicroRNA Fingerprints Identify miR-150 as a Plasma Prognostic Marker in Patients with Sepsis , 2009, PloS one.

[52]  P. Tak,et al.  MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. , 2009, Arthritis and rheumatism.

[53]  S. Brant,et al.  MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. , 2008, Gastroenterology.

[54]  Barbara Jarzab,et al.  Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma , 2008, Proceedings of the National Academy of Sciences.

[55]  Keiichiro Nishida,et al.  Expression of microRNA-146 in rheumatoid arthritis synovial tissue. , 2008, Arthritis and rheumatism.

[56]  M. Lindsay,et al.  Rapid Changes in MicroRNA-146a Expression Negatively Regulate the IL-1β-Induced Inflammatory Response in Human Lung Alveolar Epithelial Cells1 , 2008, The Journal of Immunology.

[57]  Zhen Lin,et al.  Epstein-Barr Virus Latent Membrane Protein 1 Induces Cellular MicroRNA miR-146a, a Modulator of Lymphocyte Signaling Pathways , 2007, Journal of Virology.

[58]  Z. Xu,et al.  Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients , 2007, Lupus.

[59]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[60]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[61]  M. Kerin,et al.  The use of circulating microRNAs as diagnostic biomarkers in colorectal cancer. , 2015, Cancer biomarkers : section A of Disease markers.